Clinical Trial Update: A Two-Week Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight Gain [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the efficacy and safety of mifepristone to prevent olanzapine-induced weight gain has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Obesity
• Schizophrenia
• Weight Gain

Drugs mentioned

• Mifepristone (mifepristone)

Snippet

Sponsor: Corcept Therapeutics | Conditions: Weight-Gain Prevention | Phase 2 | Status: COMPLETED